← Patent-cliff monitor small molecule CALQUENCE ACALABRUTINIB MALEATE
Loss of exclusivity July 2036 latest FDA-listed patent expiry
Company ASTRAZENECA UK LTD
Drug detail Brand name CALQUENCE Active ingredient ACALABRUTINIB MALEATE Strength EQ 100MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval August 2022 Marketing status RX
Listed patents Patent Expires Type 11059829 July 2036 substance, product 11166951 August 2035 use U-4431 11771696 January 2035 use U-3710 10272083 January 2035 use U-2687 9758524 July 2032 use U-2145 10239883 July 2032 use U-2668 9290504 July 2032 substance, product 7459554 November 2026 substance
Regulatory exclusivity Code Expires D-200 February 2029 I-960 January 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.